Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase, Fueled by GLP-1 Surge and Expanding Oral Treatments | DataM Intelligence [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
Although precise market size figures for this report were not publicly disclosed in full, broader indicators show the weight-loss/obesity therapeutics subset rising from US$ 3.30 billion in 2023 to US$ 3.92 billion in 2024 , and projected to approach US$ 20.84 billion by 2033 at a CAGR of approximately . This trajectory reflects the dramatic increase in demand for pharmacological treatments of obesity, driven by breakthrough drug classes and evolving clinical guidelines recognising obesity as a chronic disease. DataM Intelligence 4Market Research LLP - Logo Download PDF Brochure: https://www.datamintelligence.com/download-sample/competitive-landscape-of-the-global-obesity-therapeutics-market Browse in-depth TOC on 'Competitive Landscape of Obesity Therapeutics Market' 70 – Tables 66 – Figures 195 – Pages Competitive Landscape According to DataM Intelligence, key players in the obesity therapeutics market include: AstraZeneca Rhythm Pharmaceuticals, Inc. Takeda Pharmace
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- American Neurology Summit 2025 Achieves Major Success With Full Attendance and High EngagementPR Web
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 12/4/25 - Form 144
- 11/28/25 - Form 6-K
- 11/13/25 - Form 13F-HR
- TAK's page on the SEC website